Retinoic acid receptor activity is required for the maintenance of type 1 innate lymphoid cells

Takuma Asahi[1,2], Shinya Abe[1,2], Yuya Tajika[1,3], Hans-Reimer Rodewald[4], Veronika Sexl[5], Hiroshi Takeshima[3], and Koichi Ikuta[1,*]

[1]Laboratory of Immune Regulation, Department of Virus Research, Institute for Life and Medical Sciences, Kyoto University, Kyoto 606-8507, Japan; [2]Graduate School of Medicine, Kyoto University, Kyoto 606-8501, Japan; [3]Department of Biological Chemistry, Graduate School of Pharmaceutical Sciences, Kyoto University, Kyoto 606-8501, Japan; [4]Division of Cellular Immunology, German Cancer Research Center, Heidelberg 69120, Germany; [5]Institute of Pharmacology and Toxicology, University of Veterinary Medicine Vienna, 1210 Vienna, Austria.

*Correspondence
E-mail address: ikuta.koichi.6c@kyoto-u.ac.jp
Laboratory of Immune Regulation, Department of Virus Research, Institute for Life and Medical Sciences, Kyoto University, Kyoto 606-8507, Japan.
Tel, +81-75-751-4012; Fax, +81-75-751-4810.

Running head: RAR activity is required for ILC1 maintenance

Keywords: innate lymphoid cell; ILC1; NK cell; vitamin A; retinoic acid.

Number of pages: 19
Number of figures: 4
Number of supplementary figures: 1

Abstract 220 words

Group 1 innate lymphoid cells (G1-ILCs) are innate immune effectors critical for the response to intracellular pathogens and tumors. G1-ILCs comprise circulating natural killer (NK) cells and tissue-resident type 1 ILCs (ILC1s). ILC1s mainly reside in barrier tissues and provide the initial sources of interferon-γ (IFN-γ) to prime the protecting responses against infections, that are followed by the response of recruited NK cells. Despite such distribution differences, whether local environmental factors influence the behavior of NK cells and ILC1s is unclear. Here, we show that the signaling of retinoic acid (RA), active metabolites of vitamin A, is essential for the maintenance of ILC1s in periphery. Mice expressing RARα403, a truncated form of retinoic acid receptor α (RARα) that exerts dominant negative activity, in a lymphoid cell- or G1-ILC-specific manner showed remarkable reductions of peripheral ILC1s while NK cells were unaffected. Lymphoid cell-specific inhibition of RAR activity resulted in reduction of PD-1^{+} ILC progenitors (ILCPs), but not of common lymphoid progenitors (CLPs), suggesting the impaired commitment and differentiation of ILC1s. Transcriptome analysis revealed that RARα403-expressing ILC1s exhibited impaired proliferative states and declined expression of effector molecules. Thus, our findings demonstrate that cell-intrinsic RA signaling is required for the homeostasis and the functionality of ILC1s, which may present RA as critical environmental cues targeting local type 1 immunity against infection and cancer.

Introduction

Group 1 ILCs (G1-ILCs) play vital roles in response to intracellular infections and tumors (1,2). G1-ILCs contain circulating natural killer (NK) cells and tissue-resident type 1 ILCs (ILC1s), with similar features such as the expression of surface NK1.1 and NKp46, transcription factor T-bet, and production of abundant interferon-γ (IFN-γ) (1,3,4). In contrast, murine ILC1s are generally distinguished from NK cells by expression of CD49a as well as lack of CD49b and transcription factor Eomes (5-7). The developmental trajectory of ILC1s also clearly differ from NK cells, as evidenced by the fact that common lymphoid progenitors (CLPs) can generate both NK cells and ILC1s while $PLZF^{+}PD\text{-}1^{+}$ ILC progenitors (ILCPs), a progeny of CLPs, are committed to ILC1s, ILC2s, and ILC3s but not to NK cells (8-10). Recent studies have also shed light on the unique ILC1 roles as the early interferon- γ (IFN-γ) producers and the local mediators of type 1 immune response during virus infection and liver injury (11-13). Another important feature of ILC1s is heterogeneity among tissues; NK cells are observed as relatively uniform populations through the body whereas ILC1s represent highly diverse surface molecule expression and transcription factor requirements across organs (7,14,15), suggesting that tissue-specific cues play key roles in ILC1 regulation. However, how local environmental factors differentially regulate NK cells and ILC1s to maintain their pool size and the proper functionality is unclear.

Retinoic acid (RA), highly bioactive metabolites of vitamin A, is essential for various biological processes such as embryonic development, epithelial integrity, and immune function (16,17). Vitamin A deficiency is associated with increased various infectious diseases such as diarrhea, respiratory infections including measles, and human immunodeficiency virus (HIV) infection (18,19). Mechanistically, RA locally produced by retinaldehyde dehydrogenases (RALDH)-expressing cells binds to target cell retinoic acid receptors (RARα, β, and γ), that form heterodimers with retinoid X receptors (RXRs). RAR/RXR complexes bind to RA response elements (RAREs) to directly modulate expression of vast target genes including immune-related genes such as *Nfatc1* (20), *Il22* (21), *Il9* (22), and *Rorc* (23). RA thereby regulates T cell function, localization, and effector differentiation in the intestine (17,24). RA is also involved in ILC regulation: promoting the migration and development of ILC3s and inhibiting ILC2 development in the intestine (23,25-27). However, despite the well-known relevance between RA and infection prevention, how RA influences NK cells and ILC1s still remains unknown.

To address this question, we examined the lymphoid cell- and G1-ILC-intrinsic requirements for RAR activity in vivo by using mice carried RARα403 transgenes, a truncated form of RARα which can bind to ligands but no longer modulates transcription (28), in the Rosa26 locus (Rosa26-RARα403/+ mice) (29). Mice in which RA signaling is specifically inhibited in lymphoid cells (Il7r-Cre Rosa26-RARα403/+ mice) lacked ILC1s, in contrast to unaffected NK cells, in the liver and mesenteric lymph nodes (mLNs). In addition, ILCPs were decreased in Il7r-Cre Rosa26-RARα403/+ mice, suggesting that commitment and differentiation of ILCs depend on RAR activity. Moreover, we demonstrated that ILC1s depended on RA signaling in a cell-intrinsic manner by using Ncr1-Cre Rosa26-RARα403/+ mice, in which RAR activity is ablated specifically in G1-ILCs. Transcriptome analysis showed the impaired proliferative and functional signatures in ILC1s of Ncr1-Cre Rosa26-RARα403/+ mice. Thus, our findings reveal that RA signaling is critical for the homeostasis and functionality of peripheral ILC1s.

Methods

Mice

C57BL/6 mice were purchased from Japan SLC (Hamamatsu, Japan). Six to twelve-weeks old mice on a C57BL/6 background were analyzed. Rosa26-RARα403/+ mice (29) were kindly provided by Dr. Cathy L. Mendelsohn (Columbia University, USA) and crossed with either Ncr1-Cre transgenic (Tg) mice (30) provided by Dr. Veronika Sexl or Il7r-Cre knock-in (KI) mice (31) provided by Dr. Hans-Reimer Rodewald. All mice were maintained under specific pathogen-free conditions in the Experimental Research Center for Infectious Diseases in the Institute for Life and Medical Sciences, Kyoto University. All procedures were carried out under sevoflurane or isoflurane anesthesia to minimize animal suffering. All mouse protocols were approved by the Animal Experimentation Committee of the Institute for Life and Medical Sciences, Kyoto University.

Cell preparation and isolation

Liver and mLNs were dissociated mechanically and passed through 70-μm cell strainers (Greiner Bio-One, Milan, Italy). Adult liver leukocytes were then separated by centrifugation through 40% Percoll. Bone marrow (BM) cells were obtained by flushing out the marrow fraction of femurs and tibias using a syringe with a 27 G needle (Terumo Corporation, Tokyo, Japan).

Flow cytometry and cell sorting

Flow cytometry and cell sorting were performed on BD FACSVerse or BD LSRFortessa X-20 flow cytometers (BD Biosciences) and BD FACS Aria II or Aria III cell sorters (BD Biosciences), respectively. Data were analyzed on FlowJo software (FlowJo, Ashland, OR, USA). Debris and dead cells were excluded from analysis by forward and side scatter and propidium iodide (PI) gating. In figures, values in quadrants, gated areas, and interval gates indicate percentages in each population. For antibody staining, following fluorescent dye- or biotin-conjugated antibodies were used: CD3ε (145-2C11), NK1.1 (PK136), NKp46 (29A1.4), CD49a (HMα1), CD49b (DX5), IL-7Rα (A7R34), F4/80 (BM8), Gr-1 (RB6-8C5), CD19 (6D5), B220 (RA3-6B2), TCRβ (H57−597), FcεRI (MAR-1), PD-1 (29F.1A12), α4β7 (DATK32), Flt3 (A2F10), CD25 (PC61), Ki-67 (SolA15), Bcl-2 (BCL/10C4), and RORγt (Q31-378) (BioLegend, San Diego, CA, USA; Thermo Fisher Scientific, Waltham, MA,

USA; BD Bioscience, San Jose, CA, USA; TONBO Biosciences, San Diego, CA, USA). Early apoptosis of NK cells and ILC1s was detected using MEBCYTO Apoptosis Kit (MBL Life Science, Nagoya, Japan), and live annexin V^+ cells were termed as "Annexin V^+ cells". Biotinylated monoclonal antibodies were detected with Brilliant Violet 421-conjugated streptavidin (Thermo Fisher Scientific).

RNA sequencing (RNA-seq) and data analysis

NK cells ($CD49a^-CD49b^+$) and ILC1s ($CD49a^+CD49b^-IL\text{-}7R^+$) were freshly sorted ($2 \times 10^2$ cells) from control or Ncr1-Cre Rosa26-RARα403 mice, lysed with Buffer RLT (Qiagen, Hilden, Germany), and purified with RNAClean XP (Beckman Coulter, Brea, CA, USA). Double strand cDNA was synthesized, and sequencing libraries were constructed using SMART-seq HT Plus kit (Takara Bio, Otsu, Japan). Sequencing was performed with 150 bp paired-end reads on the Illumina HiSeq X (Illumina, San Diego, CA, USA) sequencer. fastp (32) was used to assess sequencing quality and to exclude low-quality reads and adaptor contaminations. Reads were mapped on the mouse reference genome (mm10) using HiSat2. The read counts were determined at the gene level with featureCounts. Normalization of gene expression levels and differential gene expression analysis were performed using DESeq2. Genes were considered as differentially expressed genes (DEG) when they had an adjusted p (p_{adj}) value < 0.3. Metascape (33) was used for enrichment analysis.

Statistical analysis

Statistical differences were evaluated by the two-tailed unpaired Student's *t*-test and one-way analysis of variance (ANOVA) using GraphPad Prism 8 (GraphPad Software, San Diego, California, USA). Asterisks in all figures indicate as follows: * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$, and **** $p < 0.0001$.

Data availability

The accession number for RNA-seq data of G1-ILCs in control or Ncr1-Cre Rosa26-RARα403 mice generated in this study is deposited in Gene Expression Omnibus (GEO): GSE205895.

Results and discussion

Lymphoid cell-specific inhibition of RAR activity depletes ILC1s

Vitamin A and RA promote ILC3 development whereas suppress the population sizes of ILC2s (23,26,27). Although the overall cellularity of NK1.1$^+$ G1-ILCs are unaffected by RA signaling inhibition (26,27), how RA impacts NK cells and ILC1s individually remains unclear. To address this question, we generated Il7r-Cre Rosa26-RARα403/+ mice (Il7r-Cre^{RARα403} mice) (29), in which RAR activity was inhibited in all lymphoid lineage cells (lymphoid lineage precursors such as CLPs, conventional and unconventional T cell and B cell lineages, and all ILCs and ILCPs) (31) in a dominant negative manner. In flow cytometry (FCM) analysis, NK cells and ILC1s were identified as CD49a$^-$CD49b$^+$ and CD49a$^+$CD49b$^-$ populations, respectively, within CD3$^-$NK1.1$^+$NKp46$^+$ G1-ILCs in the liver and mLNs (Fig. 1A and 1B). In both Il7r-Cre Rosa26-+/+ (Il7r-Cre^{WT}) control mice and Il7r-Cre^{RARα403} mice, CD3$^+$ T cells and CD19$^+$ B cells were normally developed (Fig. 1C and 1D). NK cells were also unchanged in Il7r-Cre^{RARα403} mice (Fig. 1E). Surprisingly, Il7r-Cre^{RARα403} mice mostly lacked ILC1s in the liver and mLNs (Fig. 1F). In addition, CD3$^+$NK1.1$^+$ NKT cells were also reduced in Il7r-Cre^{RARα403} mice (Fig. 1G). These results show that RAR activity impacts the homeostasis of innate-like lymphocytes in a subset-dependent manner and is especially critical for the presence of ILC1s.

RAR activity is involved in the ILC commitment and differentiation

To address the effects of RAR activity in ILC development, we examined whether RARα403 expression impacts the precursor fractions of ILCs, such as CLPs (Lin$^-$IL-7R$^+$FLT3$^+$) and ILCPs (Lin$^-$IL-7R$^+$FLT3$^-$α4β7$^+$PD-1$^+$) (34) (Fig. 2A). The frequency of ILCPs decreased in BM of Il7r-Cre^{RARα403} mice compared to controls, whereas the frequency of CLPs was slightly increased (p = 0.064) (Fig. 2B). We next analyzed the ILCP progenies other than ILC1s. Consistent with previous studies (23,26), the cell number of ILC3s (Lin$^-$IL-7R$^+$RORγt$^+$) were decreased in mLNs of Il7r-Cre^{RARα403} mice (Fig. 2C). In addition, ILC2s (Lin$^-$IL-7R$^+$FLT3$^-$CD25$^+$) were also reduced in BM and mLNs of Il7r-Cre^{RARα403} mice (Fig. 2D), suggesting that the effect of systemic vitamin A deficiency and treatment of RA antagonists examined so far, that suppress the ILC2 number (27,35), may differ from that of cell-intrinsic inhibition of RA signaling. It is also possible that occupancy of RXRs by RARα403 might exert unexpected effects on the function of other RXR partners, such as

VDR and PPARs (36,37), although minimal levels of expression of these genes were detected at least in NK cells and ILC1s (data not shown). Collectively, these results show that RAR activity is required for ILCPs but not CLPs, suggesting that RA promotes commitment and differentiation of ILCs but not overall development of lymphocytes.

ILC1s require RA signaling for their homeostasis in a cell-intrinsic manner

To address the G1-ILC-intrinsic requirement for RAR activity, we analyzed Ncr1-Cre Rosa26-RARα403/+ mice (Ncr1-Cre$^{RAR\alpha403}$ mice) compared with Ncr1-Cre Rosa26-+/+ (Ncr1-Cre^{WT}) controls. As expected, T cells and NKT cells were unchanged in Ncr1-Cre$^{RAR\alpha403}$ mice (Fig. 3A and 3B), consistent with specific G1-ILC targeting of Ncr1-Cre mice (30). Notably, ILC1s, but not NK cells, were significantly reduced in the liver of Ncr1-Cre$^{RAR\alpha403}$ mice (Fig. 3C and 3D). Similar trends were observed in the small intestine and the spleen (data not shown). These results demonstrate the cell-intrinsic requirement for RAR activity in ILC1s across organs.

RA signaling maintains the proliferative state and functionality of ILC1s.

An ILC1-restricted reduction in Ncr1-Cre$^{RAR\alpha403}$ mice indicates that RA signaling directly modulates the cellular state of mature ILC1s. To address the RA signaling-mediated effects in detail, we conducted bulk RNA sequencing (RNA-seq) experiments on liver NK cells, liver ILC1s, and spleen ILC1s freshly sorted from control or Ncr1-Cre$^{RAR\alpha403}$ mice. In RNA-seq experiments, liver and spleen ILC1s were identified as CD49a^{+}CD49b^{-}IL-7R^{+} G1-ILCs to achieve further purification of ILC1s (9) (Supplementary Figure S1A). Genes significantly downregulated in Ncr1-Cre$^{RAR\alpha403}$ mice compared to controls (down-DEGs) were detected and calculated in each G1-ILC population: 8 genes for NK cells, 56 genes for liver ILC1s, and 42 genes for splenic ILC1s (Fig. 4A and Supplementary Figure S1B), confirming the larger impacts of RAR activity against ILC1s than NK cells. Enrichment analysis using Metascape (33) revealed that both down-DEGs of liver and splenic ILC1s were enriched with the pathways related to proliferation and cell cycle (Fig. 4B, 4C, and 4D), whereas down-DEGs of NK cells had no enriched pathway. Consistent with this, *Mki67* gene and Ki-67 protein expression were reduced in liver ILC1s in Ncr1-Cre$^{RAR\alpha403}$ mice (Fig. 4E and 4F). We found no change in their Bcl-2 expression and the frequency of Annexin V^{+} cells (Fig. 4G and 4H), suggesting that the ILC1 survival are intact in Ncr1-Cre$^{RAR\alpha403}$ mice. These data suggest that RA activity supports the proliferation of ILC1s.

Interestingly, down-DEGs of liver ILC1s contained several chemokines (*Ccl3*, *Ccl4*, and *Xcl1*) (Fig. 4I), suggesting the impaired functionality. Since ILC1s localize in the frontline of infection and play a critical role in the priming of type 1 immune response (11), it is possible that ILC1s are involved in leukocyte recruiting or directly suppress viruses via these chemokines (38). In addition, five genes were identified as the intersection of down-DEGs in liver and splenic ILC1s (Fig. 4J), in which *Egr1* was the most variant one. RARs directly bind to RARE at the 5′-proximal region of *Egr1* and promote its expression (39-41). EGR1 has been reported to enhance chemokine expression including CCL3 and CCL4 (42-44). Thus, these results suggest the possibility that RAR activity promotes chemokine-mediated ILC1 functions via direct induction of EGR1.

Accumulating evidence has shown that RA is a critical niche factor regulating development, maintenance, and function of immune cells such as intestinal induced Tregs (iTregs) (45) and peritoneal macrophages (46). Given that, it is possible that RA-producing cells across multiple tissues provide niches for ILC1s, which locally maintain ILC1 pool size and proper functionality to immediately respond to infection. Therefore, it would be increasingly critical to determine the precise RA source for ILC1s. In the liver, RALDH expression is detected in hepatic stellate cells (47), liver sinusoidal endothelial cells (LSECs) (48), and hepatocytes (49), although their roles in vivo are not determined. Future investigations addressing the actual RA source for ILC1s will lead to further understanding of the mechanism of local immune regulation. Taken together, our findings have presented RA as a possible key regulator for the local type 1 immunity and provide mechanistic insights into the critical roles of vitamin A in infection prevention.

Funding

This work was supported by follows: the Japan Society for the Promotion of Science (JSPS) KAKENHI grant numbers 20H03501 and 20K21525 (K.I.); the Grant-in-Aid for JSPS Fellows number 21J15058 (T.A.); the Joint Usage/Research Center program of Institute for Life and Medical Sciences Kyoto University; and JSPS WISE program "The Graduate Program for Medical Innovation (MIP)" (T.A.).

Acknowledgments

We acknowledge Dr. Cathy L. Mendelsohn at Columbia University for providing Rosa26-RARα403 mice, Mr. H Miyachi and Ms. S. Kitano for manipulating mouse embryos, and members of the K. Ikuta laboratory for discussion and technical advice.

Conflicts of interest statement: the authors declared no conflicts of interest.

References

1 Fuchs, A. 2016. ILC1s in tissue inflammation and infection. *Front. Immunol.* 7:104.

2 Heymann, F. and Tacke, F. 2016. Immunology in the liver--from homeostasis to disease. *Nat. Rev. Gastroenterol. Hepatol.* 13:88.

3 Artis, D. and Spits, H. 2015. The biology of innate lymphoid cells. *Nature* 517:293.

4 Vivier, E., Artis, D., Colonna, M., Diefenbach, A., Di Santo, J. P., Eberl, G., Koyasu, S., Locksley, R. M., Mckenzie, A. N. J., Mebius, R. E., Powrie, F., and Spits, H. 2018. Innate lymphoid cells: 10 years on. *Cell* 174:1054.

5 Peng, H., Jiang, X., Chen, Y., Sojka, D. K., Wei, H., Gao, X., Sun, R., Yokoyama, W. M., and Tian, Z. 2013. Liver-resident NK cells confer adaptive immunity in skin-contact inflammation. *J. Clin. Invest.* 123:1444.

6 Daussy, C., Faure, F., Mayol, K., Viel, S., Gasteiger, G., Charrier, E., Bienvenu, J., Henry, T., Debien, E., Hasan, U. A., Marvel, J., Yoh, K., Takahashi, S., Prinz, I., de Bernard, S., Buffat, L., and Walzer, T. 2014. T-bet and Eomes instruct the development of two distinct natural killer cell lineages in the liver and in the bone marrow. *J. Exp. Med.* 211:563.

7 Sojka, D. K., Plougastel-Douglas, B., Yang, L., Pak-Wittel, M. A., Artyomov, M. N., Ivanova, Y., Zhong, C., Chase, J. M., Rothman, P. B., Yu, J., Riley, J. K., Zhu, J., Tian, Z., and Yokoyama, W. M. 2014. Tissue-resident natural killer (NK) cells are cell lineages distinct from thymic and conventional splenic NK cells. *Elife* 3:e01659.

8 Constantinides, M. G., McDonald, B. D., Verhoef, P. A., and Bendelac, A. 2014. A committed precursor to innate lymphoid cells. *Nature* 508:397.

9 Klose, C. S. N., Flach, M., Möhle, L., Rogell, L., Hoyler, T., Ebert, K., Fabiunke, C., Pfeifer, D., Sexl, V., Fonseca-Pereira, D., Domingues, R. G., Veiga-Fernandes, H., Arnold, S. J., Busslinger, M., Dunay, I. R., Tanriver, Y., and Diefenbach, A. 2014. Differentiation of type 1 ILCs from a common progenitor to all helper-like innate lymphoid cell lineages. *Cell* 157:340.

10 Constantinides, M. G., Gudjonson, H., McDonald, B. D., Ishizuka, I. E., Verhoef, P. A., Dinner, A. R., and Bendelac, A. 2015. PLZF expression maps the early stages of ILC1 lineage development. *Proc. Natl. Acad. Sci. USA.* 112:5123.

11 Weizman, O. E., Adams, N. M., Schuster, I. S., Krishna, C., Pritykin, Y., Lau, C., Degli-Esposti, M. A., Leslie, C. S., Sun, J. C., and O'Sullivan, T. E. 2017. ILC1 confer early host protection at initial sites of viral infection. *Cell* 171:795.

12 Nabekura, T., Riggan, L., Hildreth, A. D., O'Sullivan, T. E., and Shibuya, A. 2020. Type 1 innate lymphoid cells protect mice from acute liver injury via interferon-γ secretion for upregulating Bcl-xL expression in hepatocytes. *Immunity* 52:96.

13 Nabekura, T. and Shibuya, A. 2021. Type 1 innate lymphoid cells: Soldiers at the front line of immunity. *Biomedical. Journal.* 44:115.

14 McFarland, A. P., Yalin, A., Wang, S. Y., Cortez, V. S., Landsberger, T., Sudan, R., Peng, V., Miller, H. L., Ricci, B., David, E., Faccio, R., Amit, I., and Colonna, M. 2021. Multi-tissue single-cell analysis deconstructs the complex programs of mouse natural killer and type 1 innate lymphoid cells in tissues and circulation. *Immunity* 54:1320.

15 Cortez, V. S. and Colonna, M. 2016. Diversity and function of group 1 innate lymphoid cells. *Immunol. Lett.* 179:19.

16 Erkelens, M. N. and Mebius, R. E. 2017. Retinoic acid and immune homeostasis: a balancing act. *Trends Immunol.* 38:168.

17 Ghyselinck, N. B. and Duester, G. 2019. Retinoic acid signaling pathways. *Development* 146:dev167502.

18 Semba, R. D. 1994. Vitamin A, immunity, and infection. *Clin. Infect. Dis.* 19:489.

19 Stephensen, C. B. 2001. Vitamin A, infection, and immune function. *Annu. Rev. Nutr.* 21:167.

20 Maruya, M., Suzuki, K., Fujimoto, H., Miyajima, M., Kanagawa, O., Wakayama, T., and Fagarasan, S. 2011. Vitamin A-dependent transcriptional activation of the nuclear factor of activated T cells c1 (NFATc1) is critical for the development and survival of

B1 cells. *Proc. Natl. Acad. Sci. USA.* 108:722.

21 Mielke, L. A., Jones, S. A., Raverdeau, M., Higgs, R., Stefanska, A., Groom, J. R., Misiak, A., Dungan, L. S., Sutton, C. E., Streubel, G., Bracken, A. P., and Mills, K. H. 2013. Retinoic acid expression associates with enhanced IL-22 production by γδ T cells and innate lymphoid cells and attenuation of intestinal inflammation. *J. Exp. Med.* 210:1117.

22 Schwartz, D. M., Farley, T. K., Richoz, N., Yao, C., Shih, H. Y., Petermann, F., Zhang, Y., Sun, H. W., Hayes, E., Mikami, Y., Jiang, K., Davis, F. P., Kanno, Y., Milner, J. D., Siegel, R., Laurence, A., Meylan, F., and O'Shea, J. J. 2019. Retinoic acid receptor alpha represses a Th9 transcriptional and epigenomic program to reduce allergic pathology. *Immunity* 50:106.

23 Van De Pavert, S. A., Ferreira, M., Domingues, R. G., Ribeiro, H., Molenaar, R., Moreira-Santos, L., Almeida, F. F., Ibiza, S., Barbosa, I., Goverse, G., Labão-Almeida, C., Godinho-Silva, C., Konijn, T., Schooneman, D., O'Toole, T., Mizee, M. R., Habani, Y., Haak, E., Santori, F. R., Littman, D. R., Schulte-Merker, S., Dzierzak, E., Simas, J. P., Mebius, R. E., and Veiga-Fernandes, H. 2014. Maternal retinoids control type 3 innate lymphoid cells and set the offspring immunity. *Nature* 508:123.

24 Kim, C. H. 2018. Control of innate and adaptive lymphocytes by the RAR-retinoic acid axis. *Immune Netw.* 18:e1.

25 Kim, M. H., Taparowsky, E. J., and Kim, C. H. 2015. Retinoic acid differentially regulates the migration of innate lymphoid cell subsets to the gut. *Immunity* 43:107.

26 Goverse, G., Labao-Almeida, C., Ferreira, M., Molenaar, R., Wahlen, S., Konijn, T., Koning, J., Veiga-Fernandes, H., and Mebius, R. E. 2016. Vitamin A controls the presence of RORγ^{+} innate lymphoid cells and lymphoid tissue in the small intestine. *J. Immunol.* 196:5148.

27 Spencer, S. P., Wilhelm, C., Yang, Q., Hall, J. A., Bouladoux, N., Boyd, A., Nutman, T. B., Urban, J. F., Wang, J., Ramalingam, T. R., Bhandoola, A., Wynn, T. A., and Belkaid, Y. 2014. Adaptation of innate lymphoid cells to a micronutrient deficiency promotes type 2 barrier immunity. *Science* 343:432.

344 28 Tsai, S., Bartelmez, S., Heyman, R., Damm, K., Evans, R., and Collins, S. J. 1992. A
345 mutated retinoic acid receptor-alpha exhibiting dominant-negative activity alters the
346 lineage development of a multipotent hematopoietic cell line. *Genes Dev.* 6:2258.

347 29 Rosselot, C., Spraggon, L., Chia, I., Batourina, E., Riccio, P., Lu, B., Niederreither, K.,
348 Dolle, P., Duester, G., Chambon, P., Costantini, F., Gilbert, T., Molotkov, A., and
349 Mendelsohn, C. 2010. Non-cell-autonomous retinoid signaling is crucial for renal
350 development. *Development* 137:283.

351 30 Eckelhart, E., Warsch, W., Zebedin, E., Simma, O., Stoiber, D., Kolbe, T., Rülicke, T.,
352 Mueller, M., Casanova, E., and Sexl, V. 2011. A novel Ncr1-Cre mouse reveals the
353 essential role of STAT5 for NK-cell survival and development. *Blood* 117:1565.

354 31 Schlenner, S. M., Madan, V., Busch, K., Tietz, A., Läufle, C., Costa, C., Blum, C.,
355 Fehling, H. J., and Rodewald, H. R. 2010. Fate mapping reveals separate origins of T
356 cells and myeloid lineages in the thymus. *Immunity* 32:426.

357 32 Chen, S., Zhou, Y., Chen, Y., and Gu, J. 2018. fastp: an ultra-fast all-in-one FASTQ
358 preprocessor. *Bioinformatics* 34:i884.

359 33 Zhou, Y., Zhou, B., Pache, L., Chang, M., Khodabakhshi, A. H., Tanaseichuk, O.,
360 Benner, C., and Chanda, S. K. 2019. Metascape provides a biologist-oriented resource
361 for the analysis of systems-level datasets. *Nat. Commun.* 10:1523.

362 34 Yu, Y., Tsang, J. C. H., Wang, C., Clare, S., Wang, J., Chen, X., Brandt, C., Kane, L.,
363 Campos, L. S., Lu, L., Belz, G. T., Mckenzie, A. N. J., Teichmann, S. A., Dougan, G.,
364 and Liu, P. 2016. Single-cell RNA-seq identifies a PD-1^{hi} ILC progenitor and defines
365 its development pathway. *Nature* 539:102.

366 35 Wilhelm, C., Harrison, O. J., Schmitt, V., Pelletier, M., Spencer, S. P., Urban, J. F.,
367 Ploch, M., Ramalingam, T. R., Siegel, R. M., and Belkaid, Y. 2016. Critical role of
368 fatty acid metabolism in ILC2-mediated barrier protection during malnutrition and
369 helminth infection. *J. Exp. Med.* 213:1409.

370 36 Attar, P. S., Wertz, P. W., McArthur, M., Imakado, S., Bickenbach, J. R., and Roop, D.
371 R. 1997. Inhibition of retinoid signaling in transgenic mice alters lipid processing and
372 disrupts epidermal barrier function. *Mol. Endocrinol.* 11:792.

373 37 Imakado, S., Bickenbach, J. R., Bundman, D. S., Rothnagel, J. A., Attar, P. S., Wang,
374 X. J., Walczak, V. R., Wisniewski, S., Pote, J., and Gordon, J. S. 1995. Targeting
375 expression of a dominant-negative retinoic acid receptor mutant in the epidermis of
376 transgenic mice results in loss of barrier function. *Genes Dev.* 9:317.

377 38 Maghazachi, A. A. 2010. Role of chemokines in the biology of natural killer cells.
378 *Curr. Top. Microbiol. Immunol.* 341:37.

379 39 Edwards, S. A., Darland, T., Sosnowski, R., Samuels, M., and Adamson, E. D. 1991.
380 The transcription factor, Egr-1, is rapidly modulated in response to retinoic acid in P19
381 embryonal carcinoma cells. *Dev. Biol.* 148:165.

382 40 Balmer, J. E. and Blomhoff, R. 2002. Gene expression regulation by retinoic acid. *J.*
383 *Lipid. Res.* 43:1773.

384 41 Suva, L. J., Ernst, M., and Rodan, G. A. 1991. Retinoic acid increases zif268 early
385 gene expression in rat preosteoblastic cells. *Mol. Cell. Biol.* 11:2503.

386 42 Cho, S. J., Kang, M. J., Homer, R. J., Kang, H. R., Zhang, X., Lee, P. J., Elias, J. A.,
387 and Lee, C. G. 2006. Role of early growth response-1 (Egr-1) in interleukin-13-
388 induced inflammation and remodeling. *J. Biol. Chem.* 281:8161.

389 43 Ramana, C. V. and Das, B. 2021. Regulation of early growth response-1 (Egr-1) gene
390 expression by Stat1-independent type I interferon signaling and respiratory viruses.
391 *Comput. Math. Biophys.* 9:289.

392 44 Yan, S. F., Fujita, T., Lu, J., Okada, K., Shan Zou, Y., Mackman, N., Pinsky, D. J., and
393 Stern, D. M. 2000. Egr-1, a master switch coordinating upregulation of divergent gene
394 families underlying ischemic stress. *Nat. Med.* 6:1355.

395 45 Sun, C. M., Hall, J. A., Blank, R. B., Bouladoux, N., Oukka, M., Mora, J. R., and
396 Belkaid, Y. 2007. Small intestine lamina propria dendritic cells promote de novo
397 generation of Foxp3 Treg cells via retinoic acid. *J. Exp. Med.* 204:1775.

398 46 Okabe, Y. and Medzhitov, R. 2014. Tissue-specific signals control reversible program
399 of localization and functional polarization of macrophages. *Cell* 157:832.

400 47 Dunham, R. M., Thapa, M., Velazquez, V. M., Elrod, E. J., Denning, T. L., Pulendran,

B., and Grakoui, A. 2013. Hepatic stellate cells preferentially induce Foxp3^{+} regulatory T cells by production of retinoic acid. *J. Immunol.* 190:2009.

48 Neumann, K., Kruse, N., Szilagyi, B., Erben, U., Rudolph, C., Flach, A., Zeitz, M., Hamann, A., and Klugewitz, K. 2012. Connecting liver and gut: murine liver sinusoidal endothelium induces gut tropism of CD4^{+} T cells via retinoic acid. *Hepatology* 55:1976.

49 Lin, M., Zhang, M., Abraham, M., Smith, S. M., and Napoli, J. L. 2003. Mouse retinal dehydrogenase 4 (RALDH4), molecular cloning, cellular expression, and activity in 9-cis-retinoic acid biosynthesis in intact cells. *J. Biol. Chem.* 278:9856.

Figure legends

Fig. 1. Lymphoid cell-specific inhibition of RAR activity depletes ILC1s but not NK cells.
(**A–G**) Flow cytometric (FCM) analysis of liver and mLN lymphocytes in Rosa26-RARα403/+ mice, Il7r-Cre^{WT} mice, or Il7r-Cre^{RARα403} mice. Representative FCM profiles in the liver (A) and mLNs (B), the percentages (*upper*) and the cell numbers (*lower*) of T cells (C), B cells (D), NK cells (E), ILC1s (F), and NKT cells (G) in indicated tissues are shown. Data represent two to three independent experiments (n = 4–6). Data are presented as mean ± SEM. *$p < 0.05$, **$p < 0.01$, ****$p < 0.0001$.

Fig. 2. RA signaling is required for development of ILCPs.
(**A–D**) FCM analysis of CLPs, ILCPs, ILC3s, and ILC2s in Il7r-Cre^{WT} (control) or Il7r-Cre^{RARα403} mice. Representative FCM profiles in BM (A) and the percentages (*upper*) and the cell numbers (*lower*) of CLPs and ILCPs (B), ILC3s (C), and ILC2s (D) in indicated tissues are shown. Data represent two to three independent experiments (n = 3–6). Data are presented as mean ± SEM. *$p < 0.05$, **$p < 0.01$, ****$p < 0.0001$.

Fig. 3. Cell-intrinsic RAR activity is required for maintenance of peripheral ILC1s.
(**A–D**) FCM analysis of liver and mLN lymphocytes in Ncr1-Cre^{WT} or Ncr1-Cre^{RARα403} mice. Representative FCM profiles in the liver (A), the percentages of T cells and NKT cells (B), and the percentages (*upper*) and the cell numbers (*lower*) of NK cells (C) and ILC1s (D) in the liver and mLNs are shown. Data represent two to three independent experiments (n = 3–5). Data are presented as mean ± SEM. *$p < 0.05$.

Fig. 4. RA signaling supports the proliferative and functional statuses in ILC1s.
(**A**) Number of genes significantly upregulated (blue; up-DEGs) and downregulated (red; down-DEGs) in each cell population of Ncr1-Cre^{RARα403} mice compared to Ncr1-Cre^{WT} mice are shown. (**B** and **C**) Dot plots showing the enriched pathways on down-DEGs of liver (B) and spleen (C) ILC1s. Genes count indicates the number of DEGs included in the pathway. Gene ratio is the ratio of genes count to the total gene number in the pathway. (**D**) Heatmap representing normalized expression levels of the genes related to cell cycle in liver ILC1s from Ncr1-Cre^{WT} (control) or Ncr1-Cre^{RARα403} mice followed by range scaling. (**E**) Normalized read counts of *Mki67* (p_{adj} = 0.254) expressed in liver ILC1s from control or

Ncr1-Cre$^{RAR\alpha 403}$ mice. (**F–H**) FCM analysis of proliferation and survival marker expression in liver NK cells and ILC1s of Ncr1-Cre^{WT} or Ncr1-Cre$^{RAR\alpha 403}$ mice. The percentages of Ki-67^{+} cells (F), MFI levels of Bcl-2 (G), and the percentages of Annexin V^{+} cells (H) are shown. (**I**) Normalized read counts of *Ccl3* (p_{adj} = 0.013), *Ccl4* (p_{adj} = 0.203), and *Xcl1* (p_{adj} = 0.078) expressed on liver ILC1s from control or Ncr1-Cre$^{RAR\alpha 403}$ mice. (**J**) Venn diagram showing the overlap between down-DEGs of liver and spleen ILC1s. Data represent two independent experiments (F–H; n = 4–5) or are from RNA-seq experiments with three biological replicates (A–E, I, and J). Data are presented as mean ± SEM. *$p < 0.05$.

Supplementary figure legends

Supplementary Figure S1. Transcriptome analysis of G1-ILCs in Ncr1-Cre$^{RAR\alpha403}$ mice

(**A**) IL-7R expression of liver (*upper*) and spleen (*lower*) CD49a^{+}CD49b^{-} G1-ILCs in Ncr1-Cre^{WT} or Ncr1-Cre$^{RAR\alpha403}$ mice. (**B**) Volcano plots showing gene expression of each G1-ILC population in Ncr1-Cre^{WT} (control) mice relative to that in Ncr1-Cre$^{RAR\alpha403}$ mice. Genes significantly downregulated (red; down-DEGs) or upregulated (blue; up-DEGs) in each cell population of Ncr1-Cre$^{RAR\alpha403}$ mice are highlighted. p_{adj}, adjusted p value. FC, fold change. Data represent three (liver) and one (spleen) experiments (A) or are from RNA-seq experiments with three biological replicates (B).

Figure 1


A
Liver PI⁻ live cells
R26-RARα403
Il7r-Cre^WT
Il7r-Cre^RARα403
NK1.1
NKp46
CD49a
CD3ε
CD49b
7.25
NKT
T
97.1
22.2
ILC1
NK
4.35
97.3
25.4
5.32
97.3
0.69
B
mLN CD3⁻ NK1.1⁺NKp46⁺ G1-ILC
8.45
0.67
C
T
Liver
mLN
D
B
E
NK
F
ILC1
G
NKT
Frequency (%)
Cell number (×10⁶)
Cell number (×10⁴)
n.s.
****
**
*
Il7r-Cre^WT
Il7r-Cre^RARα403

Figure 2


A
BM PI⁻ live cells
Il7r-Cre^WT
Il7r-Cre^RARα403
IL-7R
CD25
α4β7
0.33
0.37
ILC2 18.0
CLP 55.1
24.0
8.91
53.3
33.5
ILCP 11.2
2.71
Lin
FLT3
PD-1
B
BM
CLP
ILCP
C
mLN
ILC3
D
BM
mLN
ILC2
ILC2
Frequency (%)
Cell number (×10⁴)
p = 0.064
*
n.s.
****
**
p = 0.091
p = 0.085
Il7r-Cre^WT
Il7r-Cre^RARα403

Figure 3


A
Liver PI⁻ live cells
Ncr1-Cre^WT
Ncr1-Cre^RARα403
NK1.1
NKp46
CD49a
CD3ε
CD3ε
CD49b
4.60
2.56
21.7
3.14
3.16
19.3
93.6
93.5
21.0
7.73
B
T
Liver
mLN
Frequency (%)
NKT
Liver
mLN
Frequency (%)
n.s.
C
NK
Liver
mLN
Frequency (%)
Cell number (×10⁴)
n.s.
D
ILC1
Liver
mLN
Frequency (%)
Cell number (×10⁴)
*
n.s.
Ncr1-Cre^WT
Ncr1-Cre^RARα403

Figure 4


A
Number of DEGs
Liver NK
Liver ILC1
Spleen ILC1
Up-DEG
Down-DEG
B
Liver ILC1
mitotic cell cycle process
Reg. of APC/C activators between G1/S and early anaphase
reg. of cytokine production
cytokinesis
pos. reg. of interleukin-1 beta production
meiotic cell cycle
neg. reg. of protein modification process
neg. reg. of cytokine production
lymphocyte differentiation
-(LogP)
Gene ratio
Genes count
C
Spleen ILC1
neg. reg. of cell projection organization
reg. of leukocyte proliferation
neg. reg. of T cell activation
cytokine-mediated signaling pathway
-(LogP)
Gene ratio
Genes count
D
Control
RARα403
Cdc20
Ncaph
Kif4
Cdk1
Cep55
Spc25
Ube2c
Nusap1
Stmn1
Bub1b
E
Mki67
Normalized read count (×10²)
Ncr1-Cre^WT
Ncr1-Cre^RARα403
F
Ki-67
NK
ILC1
Frequency (%)
n.s.
*
G
Bcl-2
NK
ILC1
MFI (×10³)
n.s.
H
Annexin V
NK
ILC1
Frequency (%)
n.s.
I
Ccl3
Ccl4
Xcl1
Normalized read count (×10²)
J
Egr1
Gimap7
Filip1l
Gimap6
Gimap4
51
5
37
Liver ILC1
Spleen ILC1

Supplementary Figure S1